☆ 4.6 Article

Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment-A Retrospective Multicenter Analysis

CANCERS (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer

Alejandra Bernardini et al.

Summary: Metastatic urothelial carcinoma is a difficult-to-cure disease with limited treatment options. Vinflunine has shown some improvement in overall survival and is still used for patients who are refractory to chemotherapy and immunotherapy. However, there is a lack of biomarkers to identify responding patients and alternative therapies after treatment failure.

CANCERS (2022)

Add to Collection

Article Oncology

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

T. Powles et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Oncology

Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need

Kamaneh Montazeri et al.

Summary: Metastatic urothelial carcinoma (mUC) remains a fatal malignancy, and despite recent advancements in treatments such as immune check point inhibitors (ICIs), FGFR inhibitors, and ADCs, the survival rates are still poor. Promising new agents are being studied, toxicities with current treatments are manageable, but the complex tumor biology remains a challenge for progress in therapy for mUC.

EXPERT REVIEW OF ANTICANCER THERAPY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Medicine, General & Internal

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Thomas Powles et al.

Summary: Enfortumab vedotin significantly prolonged survival compared with standard chemotherapy in patients with advanced urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor, as well as showing better progression-free survival outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Meeting Abstract Oncology

First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

Peter H. O'Donnell et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin

Susanne Deininger et al.

Summary: The study reviewed five therapy regimens for metastatic urothelial carcinoma (mUC) after checkpoint inhibitor therapy, with Enfortumab vedotin (EV) showing the best performance in terms of objective response rate, progression-free survival, and overall survival compared to chemotherapy. Further research is needed to determine the most suitable treatment approach for different patient subcollectives.

CANCERS (2021)

Add to Collection

Review Oncology

Metastatic Urothelial Cancer: a rapidly changing treatment landscape

Carlos Stecca et al.

Summary: Metastatic urothelial cancer remains incurable with limited life expectancy, but recent therapeutic advances such as immunotherapy and targeted agents have shown promising results.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)

Melissa Bersanelli et al.

Summary: This study suggests that chemotherapy is advisable for mUC patients after progression to ICI, regardless of the treatment line. The overall survival was significantly longer in patients receiving chemotherapy after ICI progression compared to those receiving other treatments or no active treatment.

CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2021)

Add to Collection

Review Urology & Nephrology

The global burden of urinary bladder cancer: an update

Anke Richters et al.

WORLD JOURNAL OF UROLOGY (2020)

Add to Collection

Article Oncology

Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study

Reut Hadash-Bengad et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Oncology

Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series

Aristotelis Bamias et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)

Add to Collection

Article Oncology

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Khalil Saleh et al.

EUROPEAN JOURNAL OF CANCER (2019)

Add to Collection

Article Urology & Nephrology

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer

Francesco Soria et al.

WORLD JOURNAL OF UROLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun V. Balar et al.

LANCET (2017)

Add to Collection

Article Oncology

Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer

Gustavo Schvartsman et al.

LUNG CANCER (2017)

Add to Collection

Article Oncology

Excellent response to chemotherapy post immunotherapy

Ashish D. Dwary et al.

ONCOTARGET (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

L. Bracci et al.

CELL DEATH AND DIFFERENTIATION (2014)

Add to Collection

Article Oncology

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

Joaquim Bellmunt et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

Joaquim Bellmunt et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.